Literature DB >> 9209372

An acute myeloid leukemia gene, AML1, regulates transcriptional activation and hemopoietic myeloid cell differentiation antagonistically by two alternative spliced forms.

T Tanaka1, K Tanaka, S Ogawa, M Kurokawa, K Mitani, Y Yazaki, Y Shibata, H Hirai.   

Abstract

The AML1 gene on chromosome 21 is disrupted in the (8;21)(q22;q22) and (3;21)(q26;q22) translocations associated with myelogenous leukemias and encodes a DNA-binding protein. From AML1 gene, two representative forms of proteins, AML1a and AML1b, are produced by an alternative splicing. Both forms have DNA-binding domain, but AML1a lacks a putative transcriptional activation domain which AML1b has. Here we demonstrate that AML1a, which solely has no effects as a transcriptional regulator, dominantly suppresses transcriptional activation by AML1b, and that AML1a exhibits the higher affinity for DNA-binding than AML1b. Furthermore a dominant negative form of AML1, AML1a, totally suppressed granulocytic differentiation otherwise induced by granulocyte colony-stimulating factor when AML1a was overexpressed in 32Dc13 murine myeloid cells. Such differentiation block by AML1a was canceled by the concomitant overexpression of AML1b. These data strongly suggest that a transcriptionally active form of AML1 is essential for the myeloid cell differentiation. In addition, we observed an altered expression level of AML1 along with the myeloid differentiation in several hemopoietic cell lines. In these cases, at least, the AML1 expression level is a potential regulator for myeloid cell differentiation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9209372

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  Variation in regulator of G-protein signaling 17 gene (RGS17) is associated with multiple substance dependence diagnoses.

Authors:  Huiping Zhang; Fan Wang; Henry R Kranzler; Raymond F Anton; Joel Gelernter
Journal:  Behav Brain Funct       Date:  2012-05-16       Impact factor: 3.759

Review 2.  Compendium of human transcription factor effector domains.

Authors:  Luis F Soto; Zhaorong Li; Clarissa S Santoso; Anna Berenson; Isabella Ho; Vivian X Shen; Samson Yuan; Juan I Fuxman Bass
Journal:  Mol Cell       Date:  2021-12-03       Impact factor: 17.970

3.  In vitro and in vivo effects on neural crest stem cell differentiation by conditional activation of Runx1 short isoform and its effect on neuropathic pain behavior.

Authors:  Nadezda Kanaykina; Klas Abelson; Dale King; Anna Liakhovitskaia; Silke Schreiner; Michael Wegner; Elena N Kozlova
Journal:  Ups J Med Sci       Date:  2010-02       Impact factor: 2.384

4.  Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.

Authors:  Tomohiro Hirade; Mariko Abe; Chie Onishi; Takeshi Taketani; Seiji Yamaguchi; Seiji Fukuda
Journal:  Int J Hematol       Date:  2015-11-21       Impact factor: 2.490

5.  Ectopic expression of HOXC6 blocks myeloid differentiation and predisposes to malignant transformation.

Authors:  Melanie Wurm; John Kowalski; Dirk Heckl; Xiao-Bing Zhang; Veronica Nelson; Brian C Beard; Hans-Peter Kiem
Journal:  Exp Hematol       Date:  2013-10-26       Impact factor: 3.084

6.  Improved eye- and skin-color prediction based on 8 SNPs.

Authors:  Katie L Hart; Shey L Kimura; Vladimir Mushailov; Zoran M Budimlija; Mechthild Prinz; Elisa Wurmbach
Journal:  Croat Med J       Date:  2013-06       Impact factor: 1.351

7.  RUNX1: an emerging therapeutic target for cardiovascular disease.

Authors:  Alexandra Riddell; Martin McBride; Thomas Braun; Stuart A Nicklin; Ewan Cameron; Christopher M Loughrey; Tamara P Martin
Journal:  Cardiovasc Res       Date:  2020-07-01       Impact factor: 10.787

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.